ivWatch Discusses Never Events in Healthcare Purchasing News
The Healthcare Purchasing News article with a focus on preventing never events states the exact number and nature of medical errors that occur annually is up for debate. Some events might be underreported and/or important details undisclosed, and that’s often the case for complications involving IVs. Within the piece, ivWatch’s Chief Nursing Officer, Susan Brown, states that despite the best care and internal programs put in place, harm from IV infiltrations and extravasations still occurs due to unique patient factors.
Yet, there’s hope for the future as “many organizations are committed to patient safety protocols and to removing the barriers that prevent accurate, honest reporting of adverse events.” Read the full article here.
ivWatch Featured Among Big Impact Businesses in Hampton Roads
ivWatch was featured among a carefully selected group of Hampton Roads-based companies in a special feature section of CoVa BIZ Magazine. The article introduces the company’s history with beginnings in President and CEO Gary Warren’s basement and covers the journey to FDA clearance for the ivWatch Model 400 as well as continued expansion plans. The article discuss the IV infiltration problem and quotes Warren about the overarching mission to keep patients safe from harm. He states, “It’s rewarding when you can solve an unmet need.” Read the full article here.
Medical Device and Diagnostic Industry Covers ivWatch/Philips Compatibility
The article, “ivWatch Finds Strong Ally in Philips to Monitor Peripheral IVs” introduces the scope of the complications associated with peripheral IV failure. The piece goes on to highlight the ivWatch Model 400 compatibility with Philips Patient Monitors and the potential to offer time-saving benefits, where ivWatch President and CEO, Gary Warren, touches on the need for more patients to have access to technology for early detection of peripheral IV infiltration, allowing for earlier intervention by the clinician. Read the full article here.
ivWatch Executive Team Quoted in Company Feature in Drug Delivery Business News & MassDevice
On the heels of a compatibility announcement with Philips Intellivue Patient Monitors, Gary Warren, president and CEO of ivWatch, and Scott Hensley, vice president of sales and business development, discuss strategic market partnerships with Drug Delivery Business News. The article discusses how the company is working to solve an unmet need in health care and Warren’s personal patient experiences as inspiration. Read the full article here.
ivWatch Model 400 includes point-of-care connectivity
HAMPTON, Va., June 21, 2018 – ivWatch, the only provider of continuous non-invasive monitoring devices for the early detection of peripheral intravenous (IV) infiltrations and extravasations, now supports Philips IntelliVue Patient Monitors for in-room and remote notifications and electronic medical record (EMR) data capture.
“Interoperability with an industry leader like Philips enables IV infiltration alerts and IV assessment data to be more widely available to health care providers,” said Gary Warren, president and CEO of ivWatch.
Already an FDA-cleared standalone device that can be integrated with any infusion pump or IV gravity infusion, the ivWatch Model 400 provides infiltration notifications through the Philips IntelliBridge EC10 Interface Module or IntelliBridge EC10 integral Interface Board with Open Interface Driver (ED101) and EC5 ID Module on MP40-90 and MX400-800 Philips patient monitors.
ivWatch visual notifications alerting clinicians of infiltration events can be displayed on a designated Philips patient monitor, as well as generated on remote nursing station monitors allowing care providers to respond quickly. Early detection of these complications helps minimize harm. In addition, a clinician is able to document the overall state/health of the IV or if there was an infiltration directly from the Model 400 user interface during a patient assessment. Integration with Philips technology enables health care facilities to leverage their current infrastructure and capture the IV assessment data in their existing EMR systems.
“Our vision is to eliminate harm associated with IV infiltrations and extravasations,” said Warren. “We will continue to work with like-minded companies to make this technology solution available to as many health care organizations as possible as we embark on a new IV therapy standard of care.”
To learn more about ivWatch and the Model 400, visit www.ivWatch.com.
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. https://www.ivWatch.com/
MEDIA CONTACT: Amara Betoney, firstname.lastname@example.org, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949
Sensors Online Announces ivWatch as a “Best of Sensors Expo” Award Finalist
Sensors Expo & Conference, the nation’s leading event focused exclusively on sensors and sensor-integrated systems, in conjunction with Sensors Online, announced ivWatch as a finalist of the 2018 Best of Sensors Expo Awards in the “Application” category. The competition highlights the advances in both innovations and real-world applications of sensors. ivWatch is one of eight companies in the running for the application award which is designed to recognize sensor use in the wider world that are distinctive and have the potential to change the way people work or serve a real industry need. Read more here.